Literature DB >> 15962523

Bevacizumab.

Lee M Ellis1.   

Abstract

Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15962523     DOI： 10.1038/nrd1727

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  24 in total

1.  Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer.

Authors:  Dijie Liu; Douglas Overbey; Lisa D Watkinson; Charles J Smith; Said Daibes-Figueroa; Timothy J Hoffman; Leonard R Forte; Wynn A Volkert; Michael F Giblin
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

2.  Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.

Authors:  Joel Hanhart; Doron S Comaneshter; Yossi Freier-Dror; Shlomo Vinker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-10       Impact factor: 3.117

3.  Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging.

Authors:  Yingding Xu; Edwin Chang; Hongguang Liu; Han Jiang; Sanjiv Sam Gambhir; Zhen Cheng
Journal:  J Nucl Med       Date:  2012-01-12       Impact factor: 10.057

4.  Biochemical and Conformational Characterization of Recombinant VEGFR2 Domain 7.

Authors:  Rossella Di Stasi; Donatella Diana; Lucia De Rosa; Roberto Fattorusso; Luca D D'Andrea
Journal:  Mol Biotechnol       Date:  2019-11       Impact factor: 2.695

5.  Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Jason Fangusaro; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Frederic Fahey; Sridhar Vajapeyam; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Maryam Fouladi; Larry E Kun
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 6.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

7.  Computer simulation of glioma growth and morphology.

Authors:  Hermann B Frieboes; John S Lowengrub; S Wise; X Zheng; Paul Macklin; Elaine L Bearer; Vittorio Cristini
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

8.  Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.

Authors:  Carolina Salvador; Bing Li; Richard Hansen; Daniel E Cramer; Maiying Kong; Jun Yan
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

9.  Induction of VEGFA mRNA translation by CoCl2 mediated by HuR.

Authors:  Cecilia Osera; Jennifer L Martindale; Marialaura Amadio; Jiyoung Kim; Xiaoling Yang; Christopher A Moad; Fred E Indig; Stefano Govoni; Kotb Abdelmohsen; Myriam Gorospe; Alessia Pascale
Journal:  RNA Biol       Date:  2015-09-01       Impact factor: 4.652

10.  Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials.

Authors:  Benjamin Schmidt; Hae-June Lee; Sandra Ryeom; Sam S Yoon
Journal:  Curr Angiogenes       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.